Thursday, May 15, 2014
Five years after a Genentech Inc. team proposed
that the receptor DR6
might be involved in Alzheimer's disease, the company and The Rockefeller University have concluded that
the proapoptotic pathway is unlikely to affect the most overt feature of the
disease-amyloid plaque formation.
Death receptor dead
The hope was that DR6 inhibition might enhance neuronal
branching and thus counteract the neurotoxic effects of Ab. However, the new findings suggest that
will not be the case.
L. SciBX 7(19); doi:10.1038/scibx.2014.546
Published online May 15, 2014
1. Nikolaev, A. et al. Nature 457,
2. Kallop, D.Y. et al. J. Neurosci.; published online
May 7, 2014; doi:10.1523/JNEUROSCI.4963-13.2014
Contact: Robby M. Weimer, Genentech Inc., South San
3. Olsen, O. et al. J. Neurosci.; published online
May 7, 2014; doi:10.1523/JNEUROSCI.3522-13.2014
Contact: Marc Tessier-Lavigne, The Rockefeller
University, New York, N.Y.
4. Osherovich, L. SciBX 2(8);
5. Marik, S.A. et al. J. Neurosci. 33, 14998-15003 (2013)
COMPANIES AND INSTITUTIONS MENTIONED
AC Immune S.A.,
South San Francisco, Calif.
(Xetra:MOR; Pink:MPSYF), Martinsried, Germany
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
The Rockefeller University, New York, N.Y.